Exact Sciences Corporation (EXAS)
NASDAQ: EXAS · Real-Time Price · USD
101.06
-0.07 (-0.07%)
At close: Dec 5, 2025, 4:00 PM EST
101.27
+0.21 (0.20%)
After-hours: Dec 5, 2025, 6:23 PM EST
Exact Sciences Stock Forecast
Stock Price Forecast
The 16 analysts with 12-month price forecasts for Exact Sciences stock have an average target of 76.38, with a low estimate of 46 and a high estimate of 105. The average target predicts a decrease of -24.42% from the current stock price of 101.06.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Exact Sciences stock from 20 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 11 | 11 | 11 | 5 |
| Buy | 7 | 7 | 7 | 7 | 7 | 5 |
| Hold | 2 | 2 | 4 | 4 | 3 | 10 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 20 | 22 | 22 | 21 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $85 → $105 | Strong Buy → Hold | Downgrades | $85 → $105 | +3.90% | Nov 25, 2025 |
| Benchmark | Benchmark | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 24, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $90 → $105 | Strong Buy → Hold | Downgrades | $90 → $105 | +3.90% | Nov 24, 2025 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $85 → $105 | Buy → Hold | Downgrades | $85 → $105 | +3.90% | Nov 21, 2025 |
| William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Nov 21, 2025 |
Financial Forecast
Revenue This Year
3.29B
from 2.76B
Increased by 19.40%
Revenue Next Year
3.74B
from 3.29B
Increased by 13.51%
EPS This Year
-0.72
from -5.59
EPS Next Year
0.33
from -0.72
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 3.4B | 4.0B | ||||
| Avg | 3.3B | 3.7B | ||||
| Low | 3.2B | 3.4B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 23.1% | 20.0% | ||||
| Avg | 19.4% | 13.5% | ||||
| Low | 14.5% | 3.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.59 | 0.83 | |||
| Avg | -0.72 | 0.33 | |||
| Low | -0.98 | -0.24 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.